Clinical Outcomes of Concurrent Impella-Assisted High-Risk PCI and TAVR in Patients With Complex Coronary Artery Disease and Severe Aortic Stenosis
- 1Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota
Abstract
Background: Percutaneous management of high risk, percutaneous coronary intervention (PCI) needing mechanical support for complex coronary artery disease in patients needing transcatheter aortic valve replacement for severe aortic stenosis remains incompletely defined. We report on the feasibility and safety of a single-session strategy using Impella-assisted complex high-risk PCI (IA-CHIP) followed by transcatheter aortic valve replacement (TAVR).
Methods: We conducted a multicenter retrospective study of consecutive patients undergoing simultaneous IA-CHIP and TAVR at 3 tertiary centers between January 2015 and March 2026. All patients received mechanical circulatory support with percutaneous microaxial flow pump Impella CP (Abiomed) during PCI, followed by transfemoral TAVR in the same session. Baseline demographics, procedural characteristics, and clinical outcomes were collected. The primary endpoint was in-hospital complications, including death, stroke, major bleeding (Bleeding Academic Research Consortium types 2, 3, or 5), acute kidney injury, permanent pacemaker implantation, and vascular complications.
Results: A total of 12 patients were included (median age, 79.5 years [IQR, 77.0-81.2]; 91.7% male; median Charlson Comorbidity Index of 7 [IQR, 5.8-9]). Coronary lesions mainly involved left main disease in 66% of cases. Advanced calcium modification was required in 50% of cases. The median aortic valve area was 0.86 cm2, and median mean gradient was 38 mm Hg. Procedural success for IA-CHIP and TAVR was 100%. There were no in-hospital deaths, strokes, or major vascular complications. Conduction disturbances requiring permanent pacemaker implantation occurred in 25%. An acute kidney injury occurred in 16.7% of cases, with no requirement for dialysis. The majority of patients (91.7%) were discharged home.
Conclusions: A single-session strategy of IA-CHIP followed by TAVR is feasible and safe in selected patients with complex coronary artery disease and severe aortic stenosis.
Related
- Does Concurrent Carotid Endarterectomy with Coronary Artery Bypass Grafting Improve Outcomes in Patients with Dual Arterial Disease? A Systematic Review and Meta-Analysis.
- Clinical Outcomes of Combined TAVR-PCI Versus SAVR-CABG in Patients with Aortic Stenosis and Coronary Artery Disease: A Systematic Review and Meta-Analysis
- Combined Triglyceride–High-density Lipoprotein Cholesterol Phenotypes and Cardiovascular Outcomes in Japanese Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Insights from Clinical Deep Data Accumulation System-PCI
- Comparable Clinical Characteristics and Outcomes between Patients with Total and Subtotal Coronary Occlusion during Intracoronary Acetylcholine Provocation Testing
- Machine learning-based prediction of clinical outcomes and left ventricular ejection fraction improvement after percutaneous coronary intervention in patients with reduced ejection fraction.
BibTeX
@article{rivera2026clinical,
title = {{Clinical Outcomes of Concurrent Impella-Assisted High-Risk PCI and TAVR in Patients With Complex Coronary Artery Disease and Severe Aortic Stenosis}},
author = {Frederick Berro Rivera and Brenden Ingraham and Pietro Di Santo and Trevor Simard and Benjamin Hibbert and Mandeep Singh},
journal = {Journal of the Society for Cardiovascular Angiography \& Interventions},
year = {2026},
month = aug,
doi = {10.1016/j.jscai.2026.105562},
url = {https://doi.org/10.1016/j.jscai.2026.105562},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Clinical Outcomes of Concurrent Impella-Assisted High-Risk PCI and TAVR in Patients With Complex Coronary Artery Disease and Severe Aortic Stenosis
AU - Frederick Berro Rivera
AU - Brenden Ingraham
AU - Pietro Di Santo
AU - Trevor Simard
AU - Benjamin Hibbert
AU - Mandeep Singh
PY - 2026
DA - 2026/08/13
JO - Journal of the Society for Cardiovascular Angiography & Interventions
DO - 10.1016/j.jscai.2026.105562
UR - https://doi.org/10.1016/j.jscai.2026.105562
AB - Background: Percutaneous management of high risk, percutaneous coronary intervention (PCI) needing mechanical support for complex coronary artery disease in patients needing transcatheter aortic valve replacement for severe aortic stenosis remains incompletely defined. We report on the feasibility and safety of a single-session strategy using Impella-assisted complex high-risk PCI (IA-CHIP) followed by transcatheter aortic valve replacement (TAVR). Methods: We conducted a multicenter retrospective study of consecutive patients undergoing simultaneous IA-CHIP and TAVR at 3 tertiary centers between January 2015 and March 2026. All patients received mechanical circulatory support with percutaneous microaxial flow pump Impella CP (Abiomed) during PCI, followed by transfemoral TAVR in the same session. Baseline demographics, procedural characteristics, and clinical outcomes were collected. The primary endpoint was in-hospital complications, including death, stroke, major bleeding (Bleeding Academic Research Consortium types 2, 3, or 5), acute kidney injury, permanent pacemaker implantation, and vascular complications. Results: A total of 12 patients were included (median age, 79.5 years [IQR, 77.0-81.2]; 91.7% male; median Charlson Comorbidity Index of 7 [IQR, 5.8-9]). Coronary lesions mainly involved left main disease in 66% of cases. Advanced calcium modification was required in 50% of cases. The median aortic valve area was 0.86 cm2, and median mean gradient was 38 mm Hg. Procedural success for IA-CHIP and TAVR was 100%. There were no in-hospital deaths, strokes, or major vascular complications. Conduction disturbances requiring permanent pacemaker implantation occurred in 25%. An acute kidney injury occurred in 16.7% of cases, with no requirement for dialysis. The majority of patients (91.7%) were discharged home. Conclusions: A single-session strategy of IA-CHIP followed by TAVR is feasible and safe in selected patients with complex coronary artery disease and severe aortic stenosis.
SN - 2772-9303
ER -